Kura Oncology 2016 Tipifarnib FTase Inhibitor HRAS Cancer

Kura Oncology investor presentation on Tipifarnib, a farnesyl transferase inhibitor for HRAS-mutant cancers. Phase 2 data presented at ASCO 2017 showed promising results in head and neck cancer. The company had $50M cash runway with planned phase 2 readouts in 2017.